-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Hologic’s COVID-19 Tests Detect Omicron Variant
Hologic’s COVID-19 Tests Detect Omicron Variant
MARLBOROUGH, Mass.--(BUSINESS WIRE)--#COVID19--Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19. Initially identified in South Africa and subsequently in a number of African, European and North American countries, the Omicron variant (B.1.1.529) contains approximately 30 mutations.
Hologic conducted an analysis of genetic sequences from more than 175 Omicron-infected samples obtained through GISAID (Global Initiative On Sharing All Influenza Data, ) and determined that none of the new mutations occur within regions of the genome targeted by Hologic's Aptima® SARS-CoV-2 Assay, Aptima® SARS-CoV-2/Flu Assay or Panther Fusion® SARS-CoV-2 Assay. Hologic has also received data from clinical users in Europe indicating that the Aptima SARS-CoV-2 assay detected Omicron COVID-19 infections in samples from inbound air travelers.
"We fully expect that SARS-CoV-2 will continue to evolve, as that is the natural path for viruses," said Kevin Thornal, president of the Diagnostic Solutions Division at Hologic. "We designed our assays with this in mind, and as a result, we are confident that the Omicron variant will not impact the performance of our assays."
Aptima and Panther Fusion tests run on Hologic's fully automated Panther® and Panther Fusion systems, respectively, which provide initial results in approximately three hours and can process more than 1,000 tests in 24 hours.
Hologic has provided more than 130 million SARS-CoV-2 assays to its laboratory customers, making a significant contribution to the global testing supply. More than 2,700 Panther systems are installed in clinical diagnostic laboratories around the world.
About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Forward-Looking Statements
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic's Aptima® SARS-CoV-2 Assay, Aptima® SARS-CoV-2/Flu Assay and Panther Fusion® SARS-CoV-2 Assay and the Panther® and Panther Fusion® systems. In addition, there can be no assurance that the products will be manufactured in adequate quantities to meet demand, be commercially successful, or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic, Aptima, Panther, Panther Fusion and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.
SOURCE: Hologic, Inc.
Contacts
Investor Contacts
Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
michael.watts@hologic.com
Ryan M. Simon
Vice President, Investor Relations
(858) 410-8514
ryan.simon@hologic.com
Media Contact
Jane Mazur
Vice President, Divisional Communications
(585) 355-5978
jane.mazur@hologic.com
MARLBOROUGH, Mass.--(BUSINESS WIRE)--#COVID19--Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19. Initially identified in South Africa and subsequently in a number of African, European and North American countries, the Omicron variant (B.1.1.529) contains approximately 30 mutations.
亚洲网马萨诸塞州马尔伯勒--(美国商业资讯)--#COVID19--霍洛奇公司(纳斯达克市场代码:HOLX)今天宣布,该公司的三项SARS-CoV-2检测都检测到了最近出现的引起新冠肺炎的冠状病毒的欧米克隆变种。Omicron变体(B.1.1.529)最初在南非被发现,随后在一些非洲、欧洲和北美国家被发现,它包含大约30个突变。
Hologic conducted an analysis of genetic sequences from more than 175 Omicron-infected samples obtained through GISAID (Global Initiative On Sharing All Influenza Data, ) and determined that none of the new mutations occur within regions of the genome targeted by Hologic's Aptima® SARS-CoV-2 Assay, Aptima® SARS-CoV-2/Flu Assay or Panther Fusion® SARS-CoV-2 Assay. Hologic has also received data from clinical users in Europe indicating that the Aptima SARS-CoV-2 assay detected Omicron COVID-19 infections in samples from inbound air travelers.
霍洛奇对通过GISAID(全球共享所有流感数据倡议)获得的175多个感染Omicron的样本的基因序列进行了分析,并确定没有新的突变发生在霍洛奇Aptima所针对的基因组区域内®SARS-CoV-2检测、Aptima®SARS-CoV-2/Flu检测或Panther Fusion®SARS-CoV-2检测。霍洛奇公司还收到了来自欧洲临床用户的数据,表明Aptima SARS-CoV-2检测在入境航空旅客的样本中检测到了奥米克龙新冠肺炎的感染。
"We fully expect that SARS-CoV-2 will continue to evolve, as that is the natural path for viruses," said Kevin Thornal, president of the Diagnostic Solutions Division at Hologic. "We designed our assays with this in mind, and as a result, we are confident that the Omicron variant will not impact the performance of our assays."
“我们完全预计SARS-CoV-2将继续进化,因为这是病毒的自然路径,”霍洛奇公司诊断解决方案部门总裁凯文·索纳尔(Kevin Thoronal)说。我们在设计我们的化验时就考虑到了这一点,因此,我们相信奥米克龙的变种不会影响我们的化验性能。“
Aptima and Panther Fusion tests run on Hologic's fully automated Panther® and Panther Fusion systems, respectively, which provide initial results in approximately three hours and can process more than 1,000 tests in 24 hours.
APTIMA和Panther Fusion测试分别在霍洛奇的全自动Panther®和Panther Fusion系统上运行,这两个系统可在大约3小时内提供初步结果,并可在24小时内处理1000多个测试。
Hologic has provided more than 130 million SARS-CoV-2 assays to its laboratory customers, making a significant contribution to the global testing supply. More than 2,700 Panther systems are installed in clinical diagnostic laboratories around the world.
霍洛奇公司已经向其实验室客户提供了超过1.3亿份SARS-CoV-2化验,为全球检测供应做出了重大贡献。世界各地的临床诊断实验室安装了2700多个黑豹系统。
About Hologic
关于荷兰学
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
霍洛奇公司是一家创新的医疗技术公司,主要致力于通过早期发现和治疗来改善妇女的健康和福祉。欲了解有关霍洛奇公司的更多信息,请访问网站:www.hologic.com。
Forward-Looking Statements
前瞻性陈述
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic's Aptima® SARS-CoV-2 Assay, Aptima® SARS-CoV-2/Flu Assay and Panther Fusion® SARS-CoV-2 Assay and the Panther® and Panther Fusion® systems. In addition, there can be no assurance that the products will be manufactured in adequate quantities to meet demand, be commercially successful, or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
本新闻稿可能包含涉及风险和不确定性的前瞻性信息,包括有关霍洛奇公司的Aptima®SARS-CoV-2检测、Aptima®SARS-CoV-2/Flu检测和Panther Fusion®SARS-CoV-2检测以及Panther®和Panther Fusion®系统使用的声明。此外,不能保证产品的生产数量足以满足需求、商业上的成功或达到任何预期的销售水平。霍洛奇公司明确表示,没有义务或承诺公开发布对本文中提出的任何此类陈述的任何更新或修订,以反映任何预期的变化或任何此类陈述所基于的事件、条件或环境的任何变化。
Hologic, Aptima, Panther, Panther Fusion and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.
霍洛奇、Aptima、Panther、Panther Fusion和The Science of Sure是霍洛奇公司在美国和/或其他国家和地区的注册商标。
SOURCE: Hologic, Inc.
消息来源:霍洛奇公司
Investor Contacts
Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
michael.watts@hologic.com
投资者联系人
迈克尔·瓦茨
投资者关系和公司公关副总裁
(858) 410-8588
邮箱:michael.watts@holiic.com
Ryan M. Simon
Vice President, Investor Relations
(858) 410-8514
ryan.simon@hologic.com
瑞安·M·西蒙
投资者关系部副总裁
(858) 410-8514
邮箱:ryan.simon@holiic.com
Media Contact
Jane Mazur
Vice President, Divisional Communications
(585) 355-5978
jane.mazur@hologic.com
媒体联系人
简·马祖尔
事业部传播部副总裁
(585) 355-5978
邮箱:jane.mazur@holiic.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧